Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
about
Corticosteroids for the management of cancer-related pain in adultsImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)Lenalidomide and chronic lymphocytic leukemiaImmune reconstitution in chronic lymphocytic leukemiaFinal results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesSafety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemiaLenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemiaIdentification of outcome-correlated cytokine clusters in chronic lymphocytic leukemiaTargeted treatment for chronic lymphocytic leukemia.Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)Lenalidomide in the treatment of chronic lymphocytic leukemia.Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.Ibrutinib: a paradigm shift in management of CLL.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis.Lenalidomide alone and in combination for chronic lymphocytic leukemia.Emerging therapies for refractory chronic lymphocytic leukemia.Rethinking clinical response and outcome assessment in a biologic age.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Evolution of lymphoma staging and response evaluation: current limitations and future directions.Molecular action of lenalidomide in lymphocytes and hematologic malignanciesBiological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
P2860
Q24186400-9814CD7A-DD43-45FD-B67D-FF87920899E6Q26768154-A93ABC87-A24A-4669-8D27-72F5851EDD92Q26823597-EC0FB1B4-C64D-48A2-ACF5-3905CD97AD5EQ26865561-9F50096C-773E-4640-A11A-6F9EC2DF45B2Q33396918-5D4C3303-4A01-49E0-A711-BB2B275C8112Q33423873-57992268-2F79-4962-8DF5-C8FF83F6F313Q33429161-4889EB4A-C845-4552-910B-5C0D241889AFQ34008584-BE9731D1-5338-4E41-B7A9-F2D79B852ACFQ34009041-F97F394F-26BA-47AC-BFB4-A722599D0F5DQ34253548-45203F33-67EF-471C-8DCE-2070B596B480Q34278096-6D2FA0C4-3161-45DE-B212-FBBBA600D6FBQ35033519-817984E9-A8B3-4655-B2EC-CF68554EEEBBQ35553576-3A2FA90C-6644-444E-BA32-68D6FC300F4BQ35599741-D308AB1B-1EEE-4E28-B5AE-C5B812788A77Q36003724-4A4629DD-FF75-4A13-9B7E-DB047EF61F82Q36125070-606250CD-5DEC-4F0F-ABA2-C34511027728Q36135185-429A761F-6254-43C8-A944-DA28C437F32BQ36462375-C0046D47-B8F9-4421-90B0-8B0325BA5369Q36739295-17F4D650-AD02-4BDF-8716-DD10FAF2D5ABQ36826893-B2158171-C36C-46CB-9071-6FADA6C62B04Q36862781-81A6CE47-C12A-482A-A0AF-250988A68DEAQ37605306-2B67560F-B33E-414E-BA49-97B3F90B868BQ37958036-15187E6B-7191-40F7-BA7D-AEF0454A8FA4Q37960157-415A288D-E848-4557-B936-0CBA07D75ECAQ38007853-BE5AEF22-4E8A-40AF-8892-D1DA33A9938DQ38068736-9CA52EBB-59A6-4A50-9231-388EEC3093EBQ38207143-20079F4E-75D3-462E-A9E2-E611BC061AF8Q38480777-0F68FB14-93EC-4464-8AF1-F95A05A9067AQ38550810-ECFE9C00-3AEE-4E1D-A3D6-C8E6860476CAQ38671671-77E09C71-C913-4E95-BFC4-221954D2E6DBQ39570166-9ECCBFBB-7433-46E0-AC14-38A88A493D95Q41356235-11FF4E67-6BEE-4747-8C9A-A8D392F6B185Q43596419-B4A0DF0E-E5CD-4F42-8EC5-9F011351268EQ48669191-0678FC1A-FB53-47DA-BAC4-847429E94FE4
P2860
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Tumor flare reaction associate ...... ia predicts clinical response.
@en
Tumor flare reaction associate ...... ia predicts clinical response.
@nl
type
label
Tumor flare reaction associate ...... ia predicts clinical response.
@en
Tumor flare reaction associate ...... ia predicts clinical response.
@nl
prefLabel
Tumor flare reaction associate ...... ia predicts clinical response.
@en
Tumor flare reaction associate ...... ia predicts clinical response.
@nl
P2093
P2860
P356
P1433
P1476
Tumor flare reaction associate ...... ia predicts clinical response.
@en
P2093
Asher Chanan-Khan
Austin Miller
David Lawrence
Francisco Hernandez-Illatazurri
Jerome B Zeldis
Kelvin Lee
Kena C Miller
Myron S Czuczman
Paul K Wallace
Swaminathan Padmanabhan
P2860
P304
P356
10.1002/CNCR.25748
P407
P577
2010-11-29T00:00:00Z